Moreover, sorafenib can target vascular endothelial growth factor (VEGF) [51], leading to undesirable cardiovascular events like hypertension, bleeding as well as other gastrointestinal disturbances and hand–foot skin reactions [4]. The gene discussed is VEGFA; the disease is hypertensive disorder.